KaydedilenlerDerginizi ekleyin

Dergiler / Turkish Medical Student Journal / 2019 / Cilt: 6 - Sayı: 1

SYSTEMIC CANNABIDIOL DOES NOT REDUCE COMPOUND 48/80-INDUCED ITCHING BEHAVIOR IN MICE

Hatice Demirel
Elif Baksın
Ece Önay Özgür
Ruhan Deniz Topuz
Ahmet ULUGÖL
Sayfa
1–1
Yayın Tarihi
2019-02-01
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Conclusion: Our results indicate that systemic administration of cannabidiol does not attenuate compound 48/80 induced itching behavior in mice.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Aims: Cannabinoids are chemical compounds including natural cannabinoids found in the Cannabis plant, their synthetic counterparts, and endocannabinoids.
📊
Temel Bulgular & Veri:Methods: Male Balb/c mice, weighing 20-30 g, were used.
💡
Sonuç & Katkı:Conclusion: Our results indicate that systemic administration of cannabidiol does not attenuate compound 48/80 induced itching behavior in mice.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Cannabidiol · compound 48-80 · pruritus

Abstract

Aims: Cannabinoids are chemical compounds including natural cannabinoids found in the Cannabis plant, their synthetic counterparts, and endocannabinoids. Cannabidiol, a phytocannabinoid derived from the Cannabis plant, exerts anticonvulsant, anxiolytic, anti-inflammatory, neuroprotective, analgesic effects. Although there are many similarities between the pathophysiological mechanisms of pain and itch, researches that investigate the effect of cannabinoids on itching are insufficient. Here, we aimed to examine the antipruritic effect of cannabidiol and the contribution of spinal cannabinoid receptors. Methods: Male Balb/c mice, weighing 20-30 g, were used. Itching behavior was produced by intradermal injection of compound 48/80 (100 μg/50 μl); cannabidiol (1, 3, 10 mg/kg, ip) was administered 30 minutes before compound 48/80 injections. Then, scratching of the injected site by the hind paws was videotaped for 30 minutes. Locomotor performances were assessed using a rotarod apparatus. Results: Cannabidiol had no effect on compound 48/80-induced itching behavior at any dose given; moreover, cannabidiol did not produce any impairment on motor function. AM-251, a cannabinoid receptor type 1 antagonist, and AM-630, a cannabinoid receptor type 2 antagonist were administered intrathecally to observe the contribution of spinal cannabinoid receptors to the antipruritic action of cannabidiol. We observed that cannabidol did not possess any effect on itching behaviour. Conclusion: Our results indicate that systemic administration of cannabidiol does not attenuate compound 48/80 induced itching behavior in mice.

🔖

Bu Makaleye Atıf Yap

Demirel, H., Baksın, E., Özgür, E. Ö., Topuz, R. D., ULUGÖL, A. (2019). SYSTEMIC CANNABIDIOL DOES NOT REDUCE COMPOUND 48/80-INDUCED ITCHING BEHAVIOR IN MICE. Turkish Medical Student Journal, Cilt: 6 - Sayı: 1, 1–1. https://ajindex.com/articles/809893

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (16)

  1. Davidson S, Giesler GJ. The multiple pathways for itch and their interactions with pain. Trends in Neurosciences 2010;33:550-8
  2. Ikoma A, Cevikbas F, Kempkes C et al. Anatomy and neurophysiology of pruritus. Semin Cutan Med Surg 2011;30:64-70
  3. Koga K, Chen T, Li X-Y et al. Glutamate acts as a neurotransmitter for gastrin-releasing peptide-sensitive and insensitive itch-related synaptic transmission in the mammalian spinal cord. Mol Pain 2011;7:47
  4. Gotoh Y, Omori Y, Andoh T et al. Tonic inhibition of allergic itch signaling by the descending noradrenergic system in mice. J Pharmacol Sci 2011;115:417-20
  5. Ross SE, Mardinly AR, McCord AE et al. Loss of inhibitory interneurons in the dorsal spinal cord and elevated itch in Bhlhb5 mutant mice. Neuron 2010;65:88698
  6. Cevikbas F, Steinhoff M, Ikoma A. Role of spinal neurotransmitter receptors in itch: new insights into therapies and drug development. Cns Neurosci Ther 2011;17:742-9
  7. Kuraishi Y. Potential new therapeutic targets for pathological pruritus. Biol Pharm Bull 2013;36:1228-34
  8. Ross SE. Pain and itch: insights into the neural circuits of aversive somatosensation in health and disease. Current Opinion in Neurobiology 2011;21:880-7
  9. Ulugol A. The endocannabinoid system as a potential therapeutic target for pain modulation. Balkan Med J 2014;31:115-20
  10. Grotenhermen F, Muller-Vahl K. The therapeutic potential of cannabis and cannabinoids. Dtsch Arztebl Int 2012;109:495-501
  11. Schrot RJ, Hubbard JR. Cannabinoids: medical implications. Annals of Medicine 2016;48:128-41
  12. Dvorak M, Watkinson A, McGlone F et al. Histamine-induced responses are attenuated by a cannabinoid receptor agonist in human skin. Inflammation Research 2003;52:238-45
  13. Schlosburg JE, O’Neal ST, Conrad DH et al. CB1 receptors mediate rimonabant-induced pruritic responses in mice: investigation of locus of action. Psychopharmacology 2011;216:323-31
  14. Schlosburg JE, Boger DL, Cravatt BF et al. Endocannabinoid modulation of scratching response in an acute allergenic model: a new prospective neural therapeutic target for pruritus. Journal of Pharmacology and Experimental Therapeutics 2009;329:314-23
  15. Spradley JM, Davoodi A, Gee LB et al. Differences in peripheral endocannabinoid modulation of scratching behavior in facial vs. spinally-innervated skin. Neuropharmacology 2012;63:743-9
  16. Tosun NC, Gunduz O, Ulugol A. Attenuation of serotonin-induced itch responses by inhibition of endocannabinoid degrad